Fennec Pharmaceuticals Inc. Information Request Form

See If You Qualify For Monetary Reward

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit.

Submit Transaction Detail Now (Optional)

- OR -

    An attorney-client relationship is not created with the submission of this form, nor an obligation on the part of Levi & Korsinsky or you to file a lead plaintiff motion in this matter . The information you submit is held as confidential. If, in its sole discretion, Levi & Korsinsky believes that you might be an appropriate lead plaintiff candidate, Levi & Korsinsky will contact you to discuss the matter and whether to establish an attorney client relationship. By submitting this form, you are authorizing us to contact you regarding this case and/or future cases. Additionally, by submitting this form, you agree to receive an email providing you with login details for CORE (Compensation Recovery Monitoring System) to help you monitor and track your securities. This is a complimentary service. Thank you for submitting your details to Levi & Korsinsky.

    FAX: 212-363-7171

    Levi & Korsinsky, LLP announces that a FENC class action lawsuit has been filed on behalf of investors who purchased Fennec Pharmaceuticals Inc. (FENC) securities between February 11, 2020 and August 10, 2020. For more on the FENC Lawsuit please contact us today.

    According to the Fennec Pharmaceuticals Inc. lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:

    (1) the manufacturing facilities for PEDMARK, the Company’s sole product candidate, did not comply with current good manufacturing practices; (2) as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

    If you suffered a loss in Fennec Pharmaceuticals Inc. you have until November 2, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.